The study looked at 50,000 people on the drugs

The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes medicines

Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged…

The analysis found GLP-1 drugs slashed the risk of alcohol-related hospital admission by 26% compared with other diabetes medicines

Absolute risk of alopecia was low, however

The study looked at 50,000 people on the drugs

The use of glucagon-like peptide-1 (GLP-1) receptor agonists to treat type 2 diabetes and obesity is associated with an increased risk of hair loss (alopecia) in adults with type…

Hundreds of users have been reporting hair loss to regulators in the United States and UK but new research on 50,000 people now appears to firm up the link.

The new hair loss study of 50,000 users of weight loss jabs appears to establish a link between weight loss drugs, such as Wegovy and Mounjaro, and alopecia according to the…

GLP-1 drugs such as Wegovy and Ozempic have been revolutionary for obesity and type 2 diabetes treatments, but questions remain about some of the side effects and potential…

Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged…

People on GLP-1 agonist drugs such as Mounjaro, Ozempic and Wegovy have been reporting hair loss

People taking GLP-1 drugs have a low risk of hair loss, which is significantly higher than for those on other diabetes medications, a new study has found.